Repurposing Old Drugs: Roflumilast as a Promising Therapeutic Option for Plaque Psoriasis.
Аннотация
BACKGROUND
Pathogenic studies have revealed that phosphodiesterase 4 (PDE4) plays a key role in psoriasis inflammation. This narrative review evaluates roflumilast, a potent PDE4 inhibitor available in oral and topical formulations, as a repurposed therapeutic for plaque psoriasis.
OBJECTIVE
To synthesize the mechanism of action, efficacy, safety, and clinical application of roflumilast, highlighting recent evidence and its position relative to existing therapies.
METHODS
We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library from inception to early 2026 using keywords including "roflumilast", "PDE4 inhibitor", and "plaque psoriasis".
RESULTS
Both oral and topical formulations achieve clinically meaningful improvements in PASI and IGA scores with favorable tolerability.
CONCLUSION
Roflumilast represents a convenient, cost-effective, and practical option, especially for sensitive sites and comorbid patients, although larger head-to-head trials against biologics are still needed.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.